Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Other Current Liabilities

Short-term obligations not reported separately, such as accrued expenses.

Savara Inc.NASDAQ: SVRA

Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other current liabilities rises 50.5% from a year ago

Other current liabilities stood at $1.54M at the end of Q1 FY2026, up 50.5% from a year earlier and down 80.9% from the prior quarter.

Context

  • Other current liabilities amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Other current liabilities increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other current liabilities keeps rising in the next quarterly balance sheet after a +50.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.54M-80.9% QoQ
Last fiscal yearDec 2025
$8.08M+61.1% YoY
Year agoMar 2025
$1.02M+50.5% since
Other Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.5%——
1 year+61.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Current Liabilities history

USD · from the balance sheet

Latest · FY2025
8.08M USD
Year-over-year change
+61.1%

Other Current Liabilities vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's Mar 2026 other current liabilities of $1.54M is the lowest of the 2 companies compared; the peer median is $5.91M.
  • Other current liabilities amounts to 0.7% of total assets for SVRA, versus a peer median of 1.3%.
SVRA Competitors Peer median
Other Current Liabilities for SVRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TBPHTheravance Biopharma, Inc.Mar 2026$5.91M ——1.3%
SVRASavara Inc.Mar 2026$1.54M +50.5%—0.7%
APMDApnimed, Inc.—— ———
Peer median (excluding SVRA) $5.91M——1.3%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents34.01M52.1M26.59M15.13M33.18M
Short-term Investments127.16M73.78M135.73M181.2M202.52M
Net Receivables1.14M954K1.01M1.04M1.25M
Inventory(1.14M)2.05M000
Other Current Assets1.5M(1.98M)280K455K1.29M
Total Current Assets165M128.95M165.95M202.14M241.62M
Property, Plant & Equipment (Net)73K51K270K165K100K
Goodwill00000
Intangible Assets11.27M10.66M10.96M10.34M11.64M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets251K116K387K242K84K
Total Non-current Assets11.6M10.82M11.62M10.74M11.82M
Total Assets176.6M139.78M177.56M212.88M253.44M
Account Payables1.44M1.33M3.5M4.55M5.76M
Short-term Debt8.33M0007K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities004.05M5.02M8.08M
Total Current Liabilities14.66M5.87M10.6M14.72M20.4M
Long-term Debt17.32M26.08M26.35M26.62M29.91M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities117K54K247K87K0
Total Non-current Liabilities17.44M26.13M26.6M26.71M29.91M
Total Liabilities32.1M32M37.19M41.43M50.3M
Common Stock116K116K140K173K204K
Retained Earnings(300.52M)(338.67M)(393.37M)(489.25M)(608.09M)
Accumulated OCI5K(605K)(271K)(750K)(87K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity144.5M107.78M140.37M171.45M203.13M
Total Debt25.79M26.14M26.49M26.74M29.91M
Net Debt(8.22M)(25.96M)(94K)11.61M(3.27M)

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.